Modern migraine treatment

Migraine is a chronic disease that periodically manifests as severe headaches accompanied by nausea, vomiting, photophobia and sensitivity to light and sound. Prevalence of migraine among women is estimated at 17% and 9% among men. Etiology and pathogenesis remain poorly elucidated. Involvement of genetic and functional factors of the trigeminovascular system including release of numerous neuropeptides from sensory nerve endings during the event has been demonstrated. The key role in the development of migraine attack is attributed to the calcitonin gene-related peptide and serotonin. Monoclonal antibodies directed against GCRP peptide and receptor – erenumab, galacenezumab, and fremanezumab, have been implemented in the therapy of episodic as well as chronic migraine in the past year. All pivotal trials demonstrated their safety as well as high effectiveness in the reduction of the number of days affected by headaches and migraine attacks.